Reclast (Zoledronic Acid) News and Research

RSS

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis.The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

19 Oct 2010

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis. The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

18 Oct 2010

$Osteoporosis drugs falsely implicated in rare thigh bone fractures, say new reports$

Osteoporosis drugs falsely implicated in rare thigh bone fractures, say new reports

Osteoporosis is a disease of the bones usually affecting elderly women and causes the bones to become brittle and easily breakable. Since last two years some alarming reports of women on drugs for therapy of this disease have come to notice. These reports show that these drugs intended for therapy may result in rare and serious fractures of their thigh bones where the bones break clean or may splinter. Often these fractures were not associated with any fall or impact. Moreover some of the sufferers are middle aged women in their 50’s who do not have full blown osteoporosis, a condition known as pre-osteoporosis or osteopenia.

25 Mar 2010

Zoledronic acid may save lives by strengthening immune system

An osteoporosis drug proven to save lives after hip fractures may do so by strengthening the body's immune system, according to geriatrics researchers at Duke University Medical Center.

19 Jul 2009

FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal women

Reclast (zoledronic acid) Injection has been approved by the US Food and Drug Administration (FDA) as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose. Reclast is already approved as a once-yearly infusion for the treatment of postmenopausal osteoporosis.

1 Jun 2009

Link between widely used osteoporosis drugs and heart problems probed

New research at Wake Forest University School of Medicine evaluated the link between a common class of drugs used to prevent bone fractures in osteoporosis patients and the development of irregular heartbeat.

6 Apr 2009

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

New data released demonstrates that the addition of Zometa (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease.

14 Dec 2008

$Once a year osteoporosis jab reduces fractures and saves lives$

Once a year osteoporosis jab reduces fractures and saves lives

A once a year injection of an osteoporosis drug has been found to reduce the number of new hip fractures for older people and also saves lives.

18 Sep 2007

Once a year treatment for osteoporosis now available in the U.S.

A once-a-year treatment for the bone-thinning disease osteoporosis has been given approval by the Food and Drug Administration (FDA) in the United States.

20 Aug 2007

$Treatment with zoledronic acid effective in reducing fractures in women with postmenopausal osteoporosis$

Treatment with zoledronic acid effective in reducing fractures in women with postmenopausal osteoporosis

A treatment for osteoporosis delivered once a year is as effective as current monthly or weekly osteoporosis regimens at reducing the incidence of bone fractures, according to a new study led by a UCSF research team.

4 May 2007

Reclast found to cause abnormal heart rhythms

An osteoporosis drug with the potential to cut the risk of spine fractures by 70 percent and the chance of hip fractures by 41 percent, has been found to have an adverse side effect on some women.

3 May 2007